Jump to content

NOTCH3

From Wikipedia, the free encyclopedia
(Redirected from Notch 3)

NOTCH3
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesNOTCH3, CADASIL, CASIL, IMF2, LMNS, CADASIL1, notch 3, notch receptor 3
External IDsOMIM: 600276; MGI: 99460; HomoloGene: 376; GeneCards: NOTCH3; OMA:NOTCH3 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_000435

NM_008716

RefSeq (protein)

NP_000426

NP_032742

Location (UCSC)Chr 19: 15.16 – 15.2 MbChr 17: 32.34 – 32.39 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Neurogenic locus notch homolog protein 3 (Notch 3) is a protein that in humans is encoded by the NOTCH3 gene.[5][6]

Function

[edit]

This gene encodes the third discovered human homologue of the Drosophila melanogaster type I membrane protein notch. In Drosophila, notch interaction with its cell-bound ligands (delta, serrate) establishes an intercellular signalling pathway that plays a key role in neural development. Homologues of the notch-ligands have also been identified in human, but precise interactions between these ligands and the human notch homologues remains to be determined.

Pathology

[edit]
Micrograph showing CADASIL with a Notch 3 immunostain

Mutations in NOTCH3 have been identified as the underlying cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).[6] Mutations in NOTCH3 have also been identified in families with Alzheimer's disease.[7] Adult Notch3 knock-out mice show incomplete neuronal maturation in the spinal cord dorsal horn, resulting in permanently increased nociceptive sensitivity.[8] Mutations in NOTCH3 are associated to lateral meningocele syndrome.[9]

Pharmaceutical target

[edit]

Notch3 is being investigated as a target for anti-cancer drugs, as it is overexpressed in several types of cancers.[10] Early clinical trials of Pfizer's PF-06650808, an anti-Notch3 antibody linked to a cytotoxic drug, showed efficacy against solid tumors.[11]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000074181Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000038146Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Sugaya K, Fukagawa T, Matsumoto K, Mita K, Takahashi E, Ando A, Inoko H, Ikemura T (September 15, 1994). "Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3". Genomics. 23 (2): 408–19. doi:10.1006/geno.1994.1517. PMID 7835890.
  6. ^ a b "Entrez Gene: NOTCH3 Notch homolog 3 (Drosophila)".
  7. ^ Guerreiro RJ, Lohmann E, Kinsella E, Brás JM, Luu N, Gurunlian N, Dursun B, Bilgic B, Santana I, Hanagasi H, Gurvit H, Gibbs JR, Oliveira C, Emre M, Singleton A (2012). "Exome sequencing reveals an unexpected genetic cause of disease: NOTCH3 mutation in a Turkish family with Alzheimer's disease". Neurobiol. Aging. 33 (5): 1008.e17–23. doi:10.1016/j.neurobiolaging.2011.10.009. PMC 3306507. PMID 22153900.
  8. ^ Rusanescu G, Mao J (2014). "Notch3 is necessary for neuronal differentiation and maturation in the adult spinal cord". J. Cell. Mol. Med. 18 (10): 2103–16. doi:10.1111/jcmm.12362. PMC 4244024. PMID 25164209.
  9. ^ Gripp KW, Robbins KM, Sobreira NL, Witmer PD, Bird LM, Avela K, Makitie O, Alves D, Hogue JS, Zackai EH, Doheny KF, Stabley DL, Sol-Church K (2014). "Truncating mutations in the last exon of NOTCH3 cause lateral meningocele syndrome". Am. J. Med. Genet. A. 167A (2): 271–81. doi:10.1002/ajmg.a.36863. PMC 5589071. PMID 25394726.
  10. ^ Purow B (2012). "Notch Inhibition as a Promising New Approach to Cancer Therapy". Notch Signaling in Embryology and Cancer. Advances in Experimental Medicine and Biology. Vol. 727. pp. 305–319. doi:10.1007/978-1-4614-0899-4_23. ISBN 978-1-4614-0898-7. PMC 3361718. PMID 22399357.
  11. ^ "Pfizer Oncology: ADC Development Overview (2016) » ADC Review".

Further reading

[edit]
[edit]